A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)

Phase 2 Completed 35 enrolled Aristea Therapeutics, Inc.

RandomizedParallel-groupDouble-blindTreatment

Summary

A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis

Timeline

Start: 2019-02-13
Primary completion: 2019-11-05
Completion: 2019-11-19

Outcome

Missed primary endpoint

registry analysis (other test); RIST4721 300 mg vs Placebo; p = 0.24; Hochberg's method NCT03988335 ↗

registry analysis (other test); RIST4721 300 mg vs Placebo; p = 0.804; Hochberg's method NCT03988335 ↗

Publications

Bissonnette R, Maari C, Tsianakas A, Reid D, McCutchan S, Baumgartner S, Mackay J, Bhakta N. A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis. Dermatol Ther (Heidelb). 2021 Dec;11(6):2179-2193. doi: 10.1007/s13555-021-00632-7. Epub 2021 Oct 30.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VIMNERIXIN	Small molecule	300 mg	Oral